| Total | AD | MixD | VaD | DLB | FTD | PDD |
---|---|---|---|---|---|---|---|
(n= 19,743) | (n= 8,139; 41%) | (n= 5,203; 27%) | (n= 4,982; 25%) | (n= 605; 3%) | (n= 409; 2%) | (n= 405; 2%) | |
Age | Â | Â | Â | Â | Â | Â | Â |
 Mean | 78.9 ± 7.8 | 77.7 ± 8.1 | 81.0 ± 6.5 | 80.0 ± 7.4 | 76.5 ± 7.1 | 70.0 ± 10.0 | 75.2 ± 7.0 |
 Range | 27 to 103 | 27 to 99 | 52 to 100 | 33 to 103 | 53 to 94 | 39 to 96 | 49 to 94 |
Gender, n (%) | Â | Â | Â | Â | Â | Â | Â |
 Female | 11,537 | 5,328 | 3,075 | 2,514 | 236 | 228 | 156 |
 | (58.0%) | (65.5%) | (59.1%) | (50.5%) | (39.0%) | (55.7%) | (38.5%) |
 Male | 8,206 | 2,811 | 2,128 | 2,468 | 369 | 181 | 249 |
 | (42.0%) | (34.5%) | (40.9%) | (49.5%) | (61.0%) | (44.3%) | (61.5%) |
MMSE | Â | Â | Â | Â | Â | Â | Â |
 Mean | 21.3 ± 5.0 | 21.6 ± 5.0 | 21.0 ± 5.0 | 21.2 ± 4.9 | 21.5 ± 5.0 | 23.6 ± 5.0 | 21.0 ± 5.1 |
 Range | 0 to 30 | 0 to 30 | 0 to 30 | 0 to 30 | 0 to 30 | 3 to 30 | 6 to 30 |
Living alone (%) | 44.3 | 43.0 | 48.7 | 45.7 | 34.7 | 33.0 | 22.7 |
CV drugs (%) | 70.0 | 59.4 | 76.9 | 84.3 | 59.5 | 53.3 | 57.5 |
ChEIs (%) | 49.8 | 73.0 | 53.9 | 7.8 | 74.4 | 6.8 | 54.6 |
NMDA antagonists (%) | 10.5 | 9.8 | 17.0 | 4.7 | 15.0 | 4.9 | 11.6 |
Number of drugs | Â | Â | Â | Â | Â | Â | Â |
 Mean | 5.0 ± 3.1 | 4.0 ± 2.8 | 5.4 ± 3.1 | 6.2 ± 3.2 | 4.8 ± 2.9 | 3.7 ± 2.8 | 6.5 ± 3.2 |
 Range | 0 to 24 | 0 to 21 | 0 to 24 | 0 to 23 | 0 to 17 | 0 to 13 | 0 to 19 |